UNSPSC 51111661: Troxacitabine

This classification denotes a pyrimidine antagonist with the molecular formula C8H11N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60KQZ0388Y, chemically known as 2(1h)-pyrimidinone, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)- but generally known as troxacitabine, which bears US NIH Compound Identifier 151173. European Medicines Agency schedules Troxacitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22612.

UNSPSC 51111661 Troxacitabine is a Commodity code covering procurement of this specific chemotherapy agent. State and local governments purchase troxacitabine primarily through health departments, public health agencies, correctional health systems, and safety-net hospitals to support cancer treatment programs and inmate healthcare. The drug is a nucleoside analog used in oncology protocols, and procurement volumes and timing are driven by patient census, clinical formulary decisions, and contractual relationships with pharmaceutical wholesalers and manufacturers. Issuing bodies tend to be state health departments and large county or municipal hospital systems that operate cancer centers or comprehensive oncology services, often coordinating purchases through group purchasing organizations or state pharmaceutical contracts to achieve volume discounts and standardized pricing.

The source contains no recent state or local contract opportunities tagged to this code. Without posted solicitations, RFPs, RFQs, or ITBs in the underlying dataset, geographic spread and current market activity cannot be characterized. Firms pursuing troxacitabine supply or distribution contracts should monitor state health department and correctional health system procurement channels directly, as well as cooperative purchasing vehicles such as state pharmacy networks and group purchasing organizations that aggregate demand across multiple jurisdictions.